Sugi Predict

Sugi Predict / Compounds / SCHEMBL482374

SCHEMBL482374

SCHEMBL482374

COCCOc1ccc(C=O)cc1OCCOC

nearest known ligand 0.77

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FDPS P14324 2/20 0.77
▸ MAPT P10636 9/20 0.66
▸ NPSR1 Q6W5P4 3/20 0.66
▸ SMN1; SMN2 Q16637 3/20 0.66
▸ LMNA P02545 2/20 0.66
▸ HTT P42858 1/20 0.66
▸ ALDH1A1 P00352 13/20 0.56
▸ TSHR P16473 1/20 0.56
▸ HPGD P15428 8/20 0.56
▸ CYP2C9 P11712 3/20 0.56
▸ CYP1A2 P05177 2/20 0.56
▸ CYP2C19 P33261 2/20 0.56
▸ CYP2D6 P10635 1/20 0.56
▸ L3MBTL1 Q9Y468 3/20 0.52
▸ TDP1 Q9NUW8 2/20 0.52
▸ NPC1 O15118 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ HSP90AA1 P07900 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30802598 0.95 FDPS (0.71) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL31268362 0.95 FDPS (0.71) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL16360861 0.95 FDPS (0.71) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL3464529 0.94 FDPS (0.69) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL2201517 0.93 FDPS (0.90) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL1515797 0.93 FDPS (0.78) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL13531028 0.92 FDPS (0.67) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL7661907 0.87 FDPS (0.86) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL5973815 0.87 FDPS (1.00) FDPSMAPTNPSR1SMN1; SMN2LMNA
SCHEMBL15952860 0.87 FDPS (0.60) FDPSMAPTNPSR1SMN1; SMN2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122059883-A Production and preparation method of erlotinib intermediate 安徽尖峰北卡药业有限公司 2026-05-19 — — CN claimed
CN-115108999-B Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2023-11-03 — — CN claimed
CN-115108999-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2022-09-27 — — CN claimed
WO-2021017996-A1 PHENYLPIPERAZINE QUINAZOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF 暨南大学 2021-02-04 — — WO claimed
CN-112300082-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2021-02-02 — — CN claimed
CN-102557977-B Synthesis intermediate of erlotinib and preparation method thereof ZHEJIANG HISUN PHARM CO LTD 2014-07-30 — — CN claimed
WO-2007138613-A2 A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) 2007-12-06 — — WO claimed
WO-2007138612-A2 A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4- YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) 2007-12-06 — — WO claimed
CN-122059883-A Production and preparation method of erlotinib intermediate 安徽尖峰北卡药业有限公司 2026-05-19 — — CN disclosed
CN-115724706-B Method for rapidly converting aldehyde group into cyano group 中国科学院兰州化学物理研究所 2024-04-12 — — CN disclosed
CN-114920704-B Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2023-11-03 — — CN disclosed
CN-115108999-B Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2023-11-03 — — CN disclosed
CN-115724706-A Method for quickly converting aldehyde group into cyano group 中国科学院兰州化学物理研究所 2023-03-03 — — CN disclosed
CN-115108999-A Phenyl piperazine quinazoline compound or pharmaceutically acceptable salt thereof, preparation method and application 暨南大学 2022-09-27 — — CN disclosed
WO-2007138613-A2 A PROCESS FOR SYNTHESIS OF [6,7-BIS-(2-METHOXYETHOXY)-QUINAZOLIN-4-YL]-(3-ETHYNYLPHENYL)AMINE HYDROCHLORIDE VITTAL MALLYA SCIENTIFIC RESEARCH FOUNDATION (IN) 2007-12-06 — — WO disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 — — US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 — — US disclosed
US-20070179151-A1 Isoquinoline aminopyrazole derivatives F. HOFMANN-LA ROCHE AG (CH) 2007-08-02 — — US disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 — — WO disclosed
WO-2007071348-A1 ISOQUINOLINE AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2007-06-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179151-A1 Isoquinoline aminopyrazole derivatives CYP3A5, CYP3A43, CYP3A4 FDPS 611/4885MAPT 2901/4885NPSR1 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.